593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies

por Ganesan, Harish, Courtney Safir, M, Bhavnani, Sujata M, Bhavnani, Sujata M, Bhavnani, Sujata M, Krause, Kevin M, Rubino, Christopher M
Publicado 2022

The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoa...

por O’Donnell, John P, Bhavnani, Sujata M
Publicado 2023

LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam...

por Bhavnani, Sujata M, Bhavnani, Sujata M, Bhavnani, Sujata M, Rubino, Christopher M, Hammel, Jeffrey P, Cammarata, Anthony P, Larson, Kajal, Liolios, Kathryn, McLeod, Sarah, Miller, Alita, Ambrose, Paul G, Tommasi, Ruben, O'Donnell, John
Publicado 2022

A Broken Antibiotic Market: Review of Strategies to Incentivize Drug Development

por Bhavnani, Sujata M, Krause, Kevin M, Ambrose, Paul G
Publicado 2020

Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods

por Zhang, Li, Wicha, Wolfgang W, Bhavnani, Sujata M, Rubino, Christopher M
Publicado 2019

1417. Evaluating the Dissonance Between C(max) and AUC with Clinically Utilized Aminoglycoside (AG) Dosing Regimens: Use of Tobramycin (TOB) Against Pseudomonas aeruginosa (PA) as...

por Onufrak, Nikolas J, Bhavnani, Sujata M, Pogue, Jason M, Rubino, Christopher M
Publicado 2018

1105. Population Pharmacokinetic Analyses for Tebipenem After the Administration of Tebipenem Pivoxil Hydrobromide

por Ganesan, Harish, Kumar, Vipul, Bhavnani, Sujata M, Melnick, David, Rubino, Christopher M
Publicado 2021

2552. Comparative Pharmacodynamic Evaluation of Commonly Utilized, Oral, 1(st) - 3(rd) Generation Cephalosporins against S. aureus and E. coli in the Mouse Thigh Infection Model

por Lepak, Alexander, Bhavnani, Sujata M, Vincent, Catharine, VanScoy, Brian D, Sader, Helio S, Andes, David
Publicado 2023

Traditional PK-PD Indices for Efficacy – Can We Do Better?

por Lakota, Elizabeth A, Bader, Justin C, Bhavnani, Sujata M, Andes, David R, Ambrose, Paul G
Publicado 2017

Antibacterial Drug Development: A New Approach Is Needed for the Field to Survive and Thrive

por Safir, M. Courtney, Bhavnani, Sujata M., Slover, Christine M., Ambrose, Paul G., Rubino, Christopher M.
Publicado 2020

2549. Pharmacometric Analyses to Support Sulbactam-Durlobactam (SUL-DUR) Dosing Regimens in Patients with Altered Renal Function

por Larson, Kajal, Bhavnani, Sujata M, Hammel, Jeffrey P, Cammarata, Anthony P, O’Donnell, John, Rubino, Christopher M
Publicado 2023

Time for Precision: A World Without Susceptibility Breakpoints

por Bader, Justin C, Lakota, Elizabeth A, Andes, David R, Rubino, Christopher M, Ambrose, Paul G, Bhavnani, Sujata M
Publicado 2018

1590. Updated Aminoglycoside (AG) MIC Breakpoints (BP) to Minimize Adverse Events and Improve Outcome: Impact on Susceptibility (S) Rates

por Pfaller, Michael A, Flamm, Robert K, Ambrose, Paul G, Andes, David, Bradley, John S, Bhavnani, Sujata M, Jones, Ronald N
Publicado 2019

1591. Updated Fluoroquinolone MIC Breakpoints: Impact on Susceptibility Rates in the United States

por Flamm, Robert K, Pfaller, Michael A, Ambrose, Paul G, Andes, David, Bradley, John S, Bhavnani, Sujata M, Jones, Ronald N
Publicado 2019

2569. Pharmacokinetic-Pharmacodynamic Evaluation of Sulopenem Using a Five-Day Hollow-Fiber In Vitro Infection Model

por VanScoy, Brian D, Conde, Haley, Vincent, Catherine E, Bhavnani, Sujata M, Aronin, Steven I, Puttagunta, Sailaja, Ambrose, Paul G
Publicado 2023

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida

por Lakota, Elizabeth A, Ganesan, Harish, Flanagan, Shawn, Ong, Voon, Sandison, Taylor, Bhavnani, Sujata M, Rubino, Christopher M, Ambrose, Paul G
Publicado 2018

1340. Population Pharmacokinetic (PK) Analysis of APX001 Using Phase 1 Data

por Trang, Michael, Bader, Justin C, Ople, Eric A, Kramer, William G, Hodges, Michael R, Bhavnani, Sujata M, Rubino, Christopher M
Publicado 2018

1561. Omadacycline Pharmacokinetics: Influence of Mortality Risk Score Among Patients with Community-Acquired Bacterial Pneumonia

por Lakota, Elizabeth A, Friedrich, Lawrence, Steenbergen, Judith N, McGovern, Paul C, Tzanis, Evan, Bhavnani, Sujata M, Rubino, Christopher M
Publicado 2019

Old In Vitro Antimicrobial Breakpoints Are Misleading Stewardship Efforts, Delaying Adoption of Innovative Therapies, and Harming Patients

por Ambrose, Paul G, Bhavnani, Sujata M, Andes, David R, Bradley, John S, Flamm, Robert K, Pogue, Jason M, Jones, Ronald N
Publicado 2020

At the Crossroads of Stewardship and Technology: Impact of Pharmacokinetic-Pharmacodynamic (PK-PD) Integrated Electronic Decision Support Software (EDSS) on the Treatment of Patien...

por Bader, Justin C, Bulik, Catharine C, Bhavnani, Sujata M, Rubino, Christopher M, Sweeney, Kim L, Ambrose, Paul G, Owens, Robert C
Publicado 2017